肠道病毒71型疫苗的中和抗体应答研究  

The study of neutralizing antibody responses induced by new entrovirus 71 vaccines

作　　者：邵杰[1,2] 毛群颖[2] 姚昕[2] 李秀玲[3] 王一平[2] 邵强[1] 刘刚[2] 梁争论[2] 李凤祥[2] 王军志[2] 

机构地区：[1]河南师范大学,新乡453007 [2]中国食品药品检定研究院,卫生部生物技术产品检定方法及其标准化重点实验室,北京100050 [3]北京生物制品研究所,北京100024

出　　处：《药物分析杂志》2013年第8期1280-1284,共5页Chinese Journal of Pharmaceutical Analysis

摘　　要：目的:比较我国不同企业研发的肠道病毒71型(EV71)疫苗原液和成品疫苗的小鼠中和抗体应答,为疫苗临床试验提供依据。方法:应用来源于3家疫苗研发企业的EV71疫苗原液(Y1、Y2、Y3),以及相应原液制备的3批成品疫苗(临床申报剂量:M1、M2、M3;相同抗原含量:M1-1、M2-1、M3-1),分别采取2针程序免疫小鼠,检测免疫1针和2针后血清中和抗体效价。结果:分别来自不同生产企业的3个EV71疫苗原液免疫原性相近,免疫剂量均为430 U/0.5 mL/只时,1针后中和抗体阳性率为83.3%～90.0%,2针均为100%,中和抗体效价分别为1∶34.9～1∶45.9和1∶139.4～1∶285.7;与Al(OH)3吸附后,3批成品疫苗的免疫原性均出现明显增强,162 U/0.5 mL/只的剂量即均可得到与430 U/0.5 mL/只原液相近的抗体阳转率和效价,2针免疫后M3-1抗体效价显著高于M1-1和M2-1(1∶357.3、1∶111.3和1∶97.9,P分别为0.004和0.001)。当3批疫苗均采用临床申报剂量免疫时(162,493,506 U/0.5 mL/只),1针免疫后中和抗体阳性率(80%～100%)和抗体效价(1∶46.8～1∶115.4)均无显著性差异(P值均>0.05),2针后中和抗体阳性率均为100%,M3批抗体效价显著高于M1批(1∶958.2、1∶316.8,P值为0.017)。结论:3家企业EV71原液的免疫原性接近,成品疫苗2针免疫后均可诱导高效价中和抗体产生,但不同企业的中和抗体升高水平呈现差别,提示临床试验中需重点比较含佐剂疫苗加免后的免疫原性。Objective： To compare the neutralizing antibody（NTAb） responses of vaccine stock solutions and final vaccines of Enterovirus 71（EV71） in mice,and provide bases for the further clinical trails of EV71 vaccines.Methods： The immunization schedule consisted of two inoculations in mice separately.ICR mice were immunized with three kinds of aqueous bulks of EV71（Y1,Y2,Y3） from three enterprises and three kinds of EV71 finial lot vaccines（Clinical declaring dose： M1,M2,M3;Equal antigenic concentration： M1-1,M2-1,M3-1）.And the NTAb titers of sera were tested after the first inoculation and the second inoculation,respectively.Results： Three kinds of aqueous bulks from different strains and preparations showed the close immunogenicity.When immunizing dose was 430 U /0.5 mL / each mouse,the positive rate of NTAb was 83.3%-90.0% after the 1st inoculation and 100% after the 2ndinoculation;with Geometric Mean Titers（GMTs） of NTAb was 1∶ 34.9-1∶ 45.9 and 1∶ 139.4 1∶ 285.7,respectively.Moreover,the immunogenicity of three bulk finished vaccines after adsorbed with Al（OH） 3 all significantly increased,in result the positive rate of NTAb of finished vaccines（162 U /0.5 mL / each mouse） was close to that of vaccine stock solutions（430 U /0.5 mL / each mouse）.After two immunizations,GMTs of M3 1 was significantly higher than that of M1-1 and M2-1（1 ∶ 357.3,1 ∶ 111.3,1 ∶ 97.9;P = 0.004 and 0.001）.When clinical declaring doses（162,493,506 U /0.5 mL / each mouse） were employed for three vaccine products,there existed no significant difference between the positive rates of NTAb（80%-100%） and between antibody GMTs（1∶ 46.8-1∶ 115.4） after the 1st inoculation（P 0.05）,and the positive rates of NTAb were all 100% after the 2nd inoculation.In addition,antibody GMTs of M3 was significantly higher than that of M1（1∶ 958.2,1∶ 316.8;P = 0.017）.Conclusion： The immunogenicity of EV71 vaccine aqueous bulk solutions from three different enterprises are close to

关 键 词：手足口病(HFMD) 肠道病毒71型(EV71) 中和抗体 免疫原性 疫苗 

分 类 号：R917[医药卫生—药物分析学]